Chembio to Commercialize Malaria Assays
Chembio Diagnostics is working to develop and launch multiple DPP malaria assays, following initial testing showing a 10-fold improvement in sensitivity of the product.
Medford, N.Y.-based Chembio plans to begin field-testing its DPP Malaria-Ebola Assay in West Africa and its DPP Fever Panel Assay to detect malaria, Dengue, Ebola, Lassa, Marburg and Chikungunya within 12 months.
The DPP Malaria-Ebola Assay is part of a research collaboration agreement with the Centers for Disease Control and Prevention, while the DPP Fever Panel Assay is being developed under a $2.1 million grant from the Paul G. Allen Ebola Program (IDDM, Oct. 23). — Jonathon Shacat